Focused On-demand Library for Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P33908

UPID:

MA1A1_HUMAN

Alternative names:

Man(9)-alpha-mannosidase; Mannosidase alpha class 1A member 1; Processing alpha-1,2-mannosidase IA

Alternative UPACC:

P33908; E7EU32; Q6P052; Q9NU44; Q9UJI3

Background:

Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA, also known as Man(9)-alpha-mannosidase and Mannosidase alpha class 1A member 1, plays a crucial role in the maturation of Asn-linked oligosaccharides. It specifically trims alpha-1,2-linked mannose residues from Man(9)GlcNAc(2) to produce Man(5)GlcNAc(2), a process vital for proper protein folding and function.

Therapeutic significance:

Understanding the role of Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA could open doors to potential therapeutic strategies. Its pivotal function in protein maturation makes it a target of interest in the development of treatments for diseases related to protein folding and glycosylation disorders.